BCMA-targeted CAR-T cell therapy for the treatment of multiple myeloma
PL454512A1Pending Publication Date: 2026-07-13LEGEND BIOTECH USA INC +1
Patent Information
- Application Number
- PL2023454512
- Authority / Receiving Office
- PL · PL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-31
- Filing Date
- 2023-08-31
- Publication Date
- 2026-07-13
Abstract
The subject of the application is BCMA-targeted CAR-T cell therapy for the treatment of multiple myeloma. The application describes methods for treating patients with multiple myeloma who have received one to three prior treatment cycles. The patient is administered infusions of chimeric antigen receptors (CARs)—T cells containing CARs capable of specifically binding to a BCMA epitope.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
BCMA-targeting chimeric antigen receptor, CD19-targeting chimeric antigen receptor, and combination therapies
US20200360431A1
BCMA-targeted car-t cell therapy for multiple myeloma
WO2022116086A1